Back to results
US 2022/0175915 A1Published application
MEDICINE FOR TREATING CANCER BY ADMINISTERING A TOLL-LIKE RECEPTOR AGONIST AND LAG-3 IgG FUSION PROTEIN
AssigneeCytlimic Inc.
InventorsTomoya MIYAKAWA, Shun DOI, Koji TAMADA
Life of this patent
Estimating the term…
Abstract
The present invention provides a medicine comprising a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.
Claims7
A medicine for treating a cancer in a patient, comprising
- a Toll-like receptor agonist,
- lymphocyte activation gene 3 (LAG-3) protein or a fusion protein of an extracellular domain of LAG-3 protein and IgG, and
- an HSP70-derived peptide consisting of SEQ ID NO:
- 7 and a GPC3-derived peptide consisting of SEQ ID NO:
- 16.
2 more elements
A medicine for inducing an immune response to a cancer cell in a patient, comprising
- a Toll-like receptor agonist,
- lymphocyte activation gene 3 (LAG-3) protein or a fusion protein of an extracellular domain of LAG-3 protein and IgG, and
- an HSP70-derived peptide consisting of SEQ ID NO:
- 7 and a GPC3-derived peptide consisting of SEQ ID NO:
- 16.
2 more elements
Dependencies are inferred from the claim text.